解除抗精神病药物处方

Swapnil Gupta, Rebecca Miller, J. Cahill
{"title":"解除抗精神病药物处方","authors":"Swapnil Gupta, Rebecca Miller, J. Cahill","doi":"10.1093/MED/9780190654818.003.0009","DOIUrl":null,"url":null,"abstract":"This chapter discusses some of reasons for considering a deprescribing intervention with neuroleptic medications, including clear instances such as irrational antipsychotic polypharmacy and off-label use, as well as other situations driven by stakeholder pressures or medical comorbidity. The indefinite prescription of antipsychotic medications for psychotic disorders such as schizophrenia is commonly considered a recommended practice, although some uncertainty remains. The confidence of treatment recommendations also hinges on the accuracy of diagnoses—syndromes and classifications which typically evolve over time. This chapter describes a collaborative process of decision-making about the long-term use of antipsychotic medications as many patients wishing to attempt to decrease or discontinue these medications may do so without support of the prescriber, risking harm. The ability of current data to identify which patients may need long-term medication management versus those who may not is lacking. Considering the potential serious neurological and metabolic side effects of these medications, a patient’s preferences versus risks must be carefully weighed. Nonpharmacological interventions that may support the reduction of antipsychotic medications (but should not yet be presented as validated alternatives, alone) include psychoeducation, strategies for early identification and management of relapse, cognitive behavioral therapy for psychosis, and open dialogue are reviewed. The process is illustrated by case examples at the end of the chapter.","PeriodicalId":296046,"journal":{"name":"Deprescribing in Psychiatry","volume":"102 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Deprescribing Antipsychotic Medications\",\"authors\":\"Swapnil Gupta, Rebecca Miller, J. Cahill\",\"doi\":\"10.1093/MED/9780190654818.003.0009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This chapter discusses some of reasons for considering a deprescribing intervention with neuroleptic medications, including clear instances such as irrational antipsychotic polypharmacy and off-label use, as well as other situations driven by stakeholder pressures or medical comorbidity. The indefinite prescription of antipsychotic medications for psychotic disorders such as schizophrenia is commonly considered a recommended practice, although some uncertainty remains. The confidence of treatment recommendations also hinges on the accuracy of diagnoses—syndromes and classifications which typically evolve over time. This chapter describes a collaborative process of decision-making about the long-term use of antipsychotic medications as many patients wishing to attempt to decrease or discontinue these medications may do so without support of the prescriber, risking harm. The ability of current data to identify which patients may need long-term medication management versus those who may not is lacking. Considering the potential serious neurological and metabolic side effects of these medications, a patient’s preferences versus risks must be carefully weighed. Nonpharmacological interventions that may support the reduction of antipsychotic medications (but should not yet be presented as validated alternatives, alone) include psychoeducation, strategies for early identification and management of relapse, cognitive behavioral therapy for psychosis, and open dialogue are reviewed. The process is illustrated by case examples at the end of the chapter.\",\"PeriodicalId\":296046,\"journal\":{\"name\":\"Deprescribing in Psychiatry\",\"volume\":\"102 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Deprescribing in Psychiatry\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1093/MED/9780190654818.003.0009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Deprescribing in Psychiatry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/MED/9780190654818.003.0009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本章讨论了考虑使用抗精神病药物进行处方性干预的一些原因,包括不合理的抗精神病药物综合用药和标签外使用等明确的实例,以及由利益相关者压力或医疗合并症驱动的其他情况。对于精神障碍,如精神分裂症,不确定的抗精神病药物处方通常被认为是一种推荐的做法,尽管仍存在一些不确定性。治疗建议的可信度还取决于诊断的准确性——症状和分类通常会随着时间的推移而变化。本章描述了一个关于长期使用抗精神病药物的协作决策过程,因为许多患者希望减少或停止使用这些药物,可能在没有处方医生支持的情况下这样做,冒着伤害的风险。目前缺乏数据来确定哪些患者可能需要长期药物管理,哪些患者可能不需要。考虑到这些药物潜在的严重神经和代谢副作用,必须仔细权衡患者的偏好与风险。本文回顾了可能支持减少抗精神病药物治疗的非药物干预措施(但尚不应单独作为经过验证的替代方案提出),包括心理教育、早期识别和复发管理策略、精神病认知行为治疗和公开对话。这一过程在本章末尾用实例加以说明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Deprescribing Antipsychotic Medications
This chapter discusses some of reasons for considering a deprescribing intervention with neuroleptic medications, including clear instances such as irrational antipsychotic polypharmacy and off-label use, as well as other situations driven by stakeholder pressures or medical comorbidity. The indefinite prescription of antipsychotic medications for psychotic disorders such as schizophrenia is commonly considered a recommended practice, although some uncertainty remains. The confidence of treatment recommendations also hinges on the accuracy of diagnoses—syndromes and classifications which typically evolve over time. This chapter describes a collaborative process of decision-making about the long-term use of antipsychotic medications as many patients wishing to attempt to decrease or discontinue these medications may do so without support of the prescriber, risking harm. The ability of current data to identify which patients may need long-term medication management versus those who may not is lacking. Considering the potential serious neurological and metabolic side effects of these medications, a patient’s preferences versus risks must be carefully weighed. Nonpharmacological interventions that may support the reduction of antipsychotic medications (but should not yet be presented as validated alternatives, alone) include psychoeducation, strategies for early identification and management of relapse, cognitive behavioral therapy for psychosis, and open dialogue are reviewed. The process is illustrated by case examples at the end of the chapter.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信